MedImmune's Second Shot at the Flu
Its FluMist nasal-spray vaccine now has a chance to shine. Too bad the biotech lacks the production capacity to fully exploit the opening
By Sarah Lacy
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.